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Background: Brain metastases confer significant morbidity and a
poorer survival in non-small cell lung cancer (NSCLC). Vascular
endothelial growth factor-targeted antiangiogenic therapies (AAT)
have demonstrated benefit for patients with metastatic NSCLC and
are expected to directly inhibit the pathophysiology and morbidity of
brain metastases, yet patients with brain metastases have been
excluded from most clinical trials of AAT for fear of intracranial
hemorrhage (ICH). The underlying risk of ICH from NSCLC brain
metastases is low, but needs to be quantitated to plan clinical trials
of AAT for NSCLC brain metastases.
Methods: Data from MD Anderson Cancer Center Tumor Registry
and electronic medical records from January 1998 to March 2006 was
interrogated. Two thousand one hundred forty-three patients with met-
astatic NSCLC registering from January 1998 to September 2005 were
followed till March 2006. Seven hundred seventy-six patients with and
1367 patients without brain metastases were followed till death, date of
ICH, or last date of study, whichever occurred first.
Results: The incidence of ICH seemed to be higher in those with
brain metastasis compared with those without brain metastases, in
whom they occurred as result of cerebrovascular accidents. How-
ever, the rates of symptomatic ICH were not significantly different.
All ICH patients with brain metastasis had received radiation ther-
apy for them and had been free of anticoagulation. Most of the brain
metastasis-associated ICH’s were asymptomatic, detected during
increased radiologic surveillance. The rates of symptomatic ICH, or
other cerebrovascular accidents in general were similar and not
significantly different between the two groups.
Conclusions: In metastatic NSCLC patients, the incidence of spon-
taneous ICH appeared to be higher in those with brain metastases
compared with those without, but was very low in both groups
without a statistically significant difference. These data suggest a
minimal risk of clinically significant ICH for NSCLC brain metas-
tasis patients and proposes having more well designed prospective
trail to see the role of AAT in this patient population.
Key Words: Bevacizumab, Intracranial hemorrhage, Brain metas-
tases, Non-small cell lung cancer.
(J Thorac Oncol. 2009;4: 333–337)
Brain metastases occur in approximately 30% of patientswith metastatic non-small cell lung cancer (NSCLC) and
confers significant morbidity and a poorer survival in these
patients.1–6 Ten percent of metastatic NSCLC patients have
brain metastases identified at the time of diagnosis of their
lung cancer, and an additional 14 to 19% of metastatic
NSCLC patients develop brain metastases later during the
course of their disease. As survival from metastatic NSCLC
improves, these latent brain metastases will become clinically
relevant problems requiring treatment.
Brain metastases are a poor prognostic sign in patients
with metastatic NSCLC with median survival of 6 months
despite the effectiveness of radiotherapy,7–9 Standard of care
radiotherapy can also cause delayed injury and neuron-cog-
nitive decline.10–15 Many patients also develop multiple new
brain metastases or recurrences after maximal radiotherapy,
leading to untreatable progressive neurologic morbidity and
death.16 These limitations of standard radiotherapy options
demand the development of newer systemic therapies for
brain metastases.
One of the most promising new approaches to the
therapy for advanced lung cancer has been the addition of
antiangiogenic therapies (AAT), a class of targeted biologic
agents that have substantially improved the therapy for mul-
tiple cancer types, including metastatic NSCLC. The first and
most widely used FDA-approved antiangiogenic agent is
Bevacizumab, a monoclonal antibody that binds and neutral-
izes vascular endothelial growth factor, the principle media-
tor of angiogenesis in growing malignancies.17–24 Bevaci-
zumab added to standard frontline chemotherapy for NSCLC
has shown to improve response rates, time to progression, and
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overall survival compared with chemotherapy alone.22,25 An-
tiangiogenic agents like Bevacizumab also are expected to
ameliorate directly the morbidity of brain metastases by
reducing peritumoral vasogenic edema, mediated by vascular
endothelial growth factor26–28 which is required for progres-
sive growth of brain metastases29 and represents and impor-
tant target for treatment of brain metastases.30
Unfortunately, patients with brain metastases have not
had access to AAT for fear of tumor-related intracranial
hemorrhage (ICH) from a choriocarcinoma brain metastasis
in the first phase I clinical trial of bevacizumab.18 It is known
although the most common tumor type to undergo brain
metastasis hemorrhage is lung cancer, or bronchogenic car-
cinoma, this is because such a large fraction of patients
with brain metastasis have bronchogenic carcinomas.33–38
However, cumulative historical and anecdotal experience
with lung cancer patients suggests that the incidence of
spontaneous NSCLC brain metastasis hemorrhage appears
to be very low.31,32,35,36
We hypothesized that the rates of spontaneous ICH
among advanced NSCLC patients with brain metastasis is not




The deidentified data reviewed includes individuals
with diagnosis of advanced NSCLC presenting to UTM-
DACC from January 1998 to September 2005. The subjects
had been followed through March 2006. The diagnosis of
brain metastasis in these patients was based on results of
radiologic imaging reivew, radiologic reports, and physician
notes. Only very small (2 mm), indeterminate, and very
slowly growing brain metastases might have been missed.
The outcome of interest was ICH—any epidural, subarach-
noid, intraventricular, or intraparenchymal hemorrhage any-
where within the central nervous system. ICH was confirmed
by review of radiologic imaging, radiologic reports, and
physician notes. Any obvious traumatic or iatrogenic hemor-
rhages were excluded.
Because ICH in patients without brain metastases
would most likely be related to cerebrovascular accidents
(CVA), we also compared as a control measure the incidence
of cerebrovascular occlusive episodes between patients with
or without brain metastases. These episodes included both
thrombotic and embolic events, ranging from transient isch-
emia to cerebral infarcts.
Sample Size
The type I error level (alpha) was set at 0.05 and type
II error at 0.20 (power 0.80). The baseline prevalence of
intratumor bleed in metastatic brain tumors has been reported
to be around 2.9%.31 A sample size of 1052 (526 per group)
was calculated to detect a twofold or greater increase in rate
of ICH in the brain metastasis patients as compared with the
no brain metastasis patients. We had a sample size of 2143
(776 exposed and 1367 unexposed) and with a baseline
incidence in no brain metastasis patients of 3.2 events per
1000 person-years and the difference of 12.3 events per 1000
person-years, the power of the study was 0.70.
Person-time of follow-up for brain metastasis and no
brain metastasis patients was calculated. All patients were
followed from the date of registration till either (1) the date of
death (2) the last day of contact, or (3) the day of occurrence
of the outcome of interest, whichever occurred first. How-
ever, if during the follow up a patient developed brain
metastasis his person-time was included under exposed from
when the brain metastasis was first recognized.
Hemorrhagic stroke (symptomatic ICH): subjects who
were symptomatic and had neurologic symptoms attributable
to the ICH were classified as those with hemorrhagic stroke.
Most patients with ICH do have symptoms. However, as all
patients with advanced NSCLC undergo routine brain imag-
ing, it was expected that asymptomatic ICH would be de-
tected in some patients during imaging.
Potential confounders included age and sex of the
patients.39 Based on available literature, it was hypothesized
that these factors could potentially be related to both risk of
brain metastasis as well as ICH. Based on previous studies,
age was categorized as less than 65 years or 65 years or
more.40–42 Information was also available on whether the
brain metatasis patients received any radiotherapy to the brain
lesions, used anticoagulants or hormonal therapy, or had a
history of hypertension as these factors may influence the risk
of intracranial bleeding.43–46
Data Management
The data was collected with the approval of the institu-
tion’s IRB and was maintained in a confidential manner. All
patient identifiers had been removed from the data set and no
personal information on any subject or medical care provider
could be obtained. All the information available in the data set
was strictly used for the purpose of this study and not shared.
RESULTS
There were a total of 2143 patients with advanced
NSCLC in the study. Out of these, 776 (36%) individuals had
brain metastasis at the time of registration. The total time of
follow-up for the brain metastasis and no brain metastasis
groups were 6961 person-months (580 person-years) and 14,
837 person-months (1236 person-years of follow-up), respec-
tively. None of the patients without brain metastases devel-
oped brain metastasis on follow-up.
Selected characteristics of the subjects depending on brain
metastasis status are shown in Table 1. There were more males
in the study as compared with females (58.2 versus 41.8%).
There were a total of 1272 (59.3%) patients who were less than
65 years of age. Within both groups with or without brain
metastases the predominant population was white (81.6 and
81.8%, respectively) followed by blacks (9.0 and 9.2%) and
Hispanics (6.3 and 5.0%). Within both groups most patients
were known to be stage IV at presentation (94.7% among those
with brain metastases and 86.2% among those without).
The prevalence of ICH among those with brain metas-
tases was 1.17% as compared with 0.30% among those
without (Table 2), a statistically significant 3.96 fold greater
risk (95% confidence interval CI 1.22–12.83; p  0.013).
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The prevalence of thromboembolic CVA among those with
brain metastases was 1.68% as compared with 2.05% among
those without (Table 2), a 0.82 fold lower risk that was not
statistically significant (95% CI 0.43–1.57; p  0.56).
The nine events of ICH within the brain metastasis
group occurred over 580 person-years of follow-up and the
four within the no brain metastasis group occurred over 1236
person-years. The incidence among those with brain metas-
tases was significantly higher as compared with those without
(15.5 events/1000 person-years versus 3.2 events/1000 per-
son-years; p  0.0076), a 4.79 fold greater risk (95% CI 
1.34–21.31) as shown in Table 3.
The incidences of symptomatic ICH, however, were not
significantly different between the brain metastasis or no
brain metastasis groups (6.9 events/1000 person-years versus
3.2 events/1000 person-years; p 0.30) as shown in Table 4.
ICH’s were symptomatic in only 4 of the 9 events within the
brain metastasis group, but in all of the four events in the no
brain metastasis group. This discrepancy in symptomatic ICH
between the two groups can be explained as follows. The
asymptomatic ICH cases were identified during surveillance
scans for patients with known brain metastases, which can
contain clinically insignificant punctuate foci of hemorrhage.
In patients without brain metastases on prior screening brain
scans, surveillance imaging was performed less frequently,
and ICH was identified only after symptomatic CVA’s.
No alternative explanations for our results could be
identified, and the Mantel Haenszel test was used to confirm
that sex and age are not potential effect modifiers or con-
founders (Tables 5 and 6). Among the 776 patients who had
brain metastasis only four patients had not received radiation
TABLE 1. Baseline Characteristics of the Study Population






Male 430 (55.4) 816 (59.7)
Female 346 (44.6) 551 (40.3)
Age
65 yr 526 (67.8) 746 (54.6)
65 yr 250 (32.2) 621 (45.4)
Race
White 633 (81.6) 1118 (81.8)
Black 70 (9.0) 126 (9.2)
Hispanic 49 (6.3) 69 (5.0)
Other 24 (3.1) 54 (4.0)
Stage
IIIA 13 (1.7) 40 (2.9)
IIIB 28 (3.6) 148 (10.9)
IV 735 (94.7) 1179 (86.2)
a Percentages are of the total; percentages are rounded of to the nearest 10th decimal.









Brain mets (N  776) 754 (97.2%) 13 (1.68%) 9 (1.17%) 4 (0.53%)
No brain mets (N  1367) 1334 (97.6%) 28 (2.05%) 4 (0.30%) 4 (0.30%)
Risk ratio (95% CI) 0.82 (0.43–1.57) 3.96 (1.22–12.22) 1.76 (0.44–7.02)
p 0.56 0.013 0.42







Person time (person-years) 580 1,236
Incidence rate (per 1000 person-years) 15.5 3.2
Crude incidence rate ratio  4.79 (95% CI  1.34–21.31); p  0.0076.
TABLE 4. Incidence Rate and Incidence Rate Ratio of Brain





Symptomatic ICH 4 4
Person time (person-years) 580 1236
Incidence rate (per 1000 person-years) 6.9 3.2
Crude incidence rate ratio  2.13 (95% CI  0.40–11.44); p  0.31.
TABLE 5. Determining Confounding and Effect
Modification by Sex
Sex RR (95% CI)
Females 6.37 (0.71–56.76)
Males 3.16 (0 .76–13.17)
Crude 3.96 (1.22–12.82)
M–H combined (adjusted) 4.03 (1.23–13.19)
Test of homogeneity (M–H) 2 (1)  0.279 Pr  2  0.5972.
TABLE 6. Determining Confounding and Effect
Modification by Age Group
Sex RR (95% CI)
65 yr 8.51 (1.03–70.47)
65 yr 2.48 (0.50–12.22)
Crude 3.96 (1.22–12.83)
M–H combined (adjusted) 4.44 (1.28–15.42)
Test of homogeneity (M–H) 2 (1)  0.874 Pr  2  0.3499.
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therapy for the brain lesions. Only one patient with brain
metastases who developed ICH had not received radiation
therapy. None of the subjects in either group were on any
known anticoagulants. There was one patient with ICH and a
history of hypertension among those with brain metastasis,
and one among those without, but their hypertension was
under control at the time of ICH. None of the patients who
developed ICH were receiving hormonal therapy.
DISCUSSION
The data presented here suggests that the risk of devel-
oping ICH in those with brain metastasis is more than in those
without brain metastases in a patient population comprised of
advanced NSCLC patients; however, this increased risk is
very small. The rates of clinically symptomatic ICH were not
significantly higher among those with brain metastasis as
compared with those without brain metastasis.
In this study, the incidence of ICH was found to be 15.5
events/1000 person-years in those with brain metastasis and
3.2 events/1000 person-years among those without; thus,
detecting the increase is more than 2-fold in those with brain
metastasis. The incidence of symptomatic ICH in patients
with brain metastasis was only 6.9 events/1000 person-years.
To our knowledge, this is the first study with a large
sample size to determine the rates of ICH in NSCLC patients
with and without brain metastasis. The rate of ICH in brain
metastases has been reported to be 2.9% previously31; how-
ever, these studies included metastasis from many different
sites and histologies, some of which form very vascular
tumors. We speculate that our low rates of ICH for NSCLC
brain metastases might be further attributable to the radiation
therapy that almost all of our patients received, because
radiotherapy seems to blunt angiogenesis, normalizing tumor
vasculature and decreasing the risk of tumor hemorrhage.47,48
Our detection of asymptomatic ICH in patients with brain
metastases may at least in part be related to the practice of
more frequent surveillance imaging in these patients.
Our patient groups were designated based on the pres-
ence or absence of brain metastases known at the time of
death or the last clinic encounter. Although it is possible that
some patients in the no brain metastasis group could have
developed them by the time of death, none of these patients
had visible brain metastases at the time of ICH or ischemic
CVA. Conversely, although it is possible that patients in the
brain metastasis group could have developed the metastases
after the reported CVA, all of these patients had visible brain
metastases at the time of ICH or ischemic CVA. Our preva-
lence of detectable brain metastases in patients with meta-
static NSCLC was 36%, consistent with reported rates be-
tween 30 and 40%.2–5 Prior studies have reported decreased
survival and increased risk of ICH with large metastatic brain
tumors in patients with advanced NSCLC.49 It is notable that
in the present study the four patients who developed clinically
symptomatic ICH had tumors 2 cm in size, whereas hem-
orrhage in smaller lesions were likely to remain asymptom-
atic. However, data on tumor sizes was not available for all
cases, and we can only conjecture that tumor size correlates
with symptomatic ICH.
Three major limitations must be considered when re-
viewing these results. Patients evaluated were from a tertiary
level referral center, which may produce several selection
biases. The patient populations considered may have more
advanced disease. An unusual hetereogeneity of socioeco-
nomic groups from indigent to affluent with a broad range in
access to health care may also influence the extent of disease
upon presentation. The majority of the patients in our study
were White so it may not be possible to extrapolate our
results to other ethnicities. Another limitation is that with the
limited sample size and low rates of symptomatic ICH in the
two groups, the study’s statistical power was inadequate to
comment on the statistical significance of the association.
Finally, we did not have data on the RPA classification data
on the patients as per the RTOG prognostication categoriza-
tion. Thus, we were unable to adjust the data for patient’s
RPA classification status.
The notable strengths of this study include the follow-
ing. This is one of the largest studied cohorts of patients with
advanced NSCLC with or without brain metastases. The data
were abstracted from radiologic images, reports, and clinic
physician dictations allowing greater accuracy. Data on the exact
person-time of follow-up from each patient was available. Fi-
nally, chances of differential misclassification were reduced
since the exposure was measured before the outcome.
A low incidence of ICH was observed, and the rates of
clinically symptomatic ICH in patients with brain metastasis
were even lower. This study suggests that in patients with
advanced NSCLC and brain metastasis who have stable
disease, a history of radiation therapy, and small tumor size,
it may be reasonable to include them in trials testing role of
AAT, without a significant a priori risk of ICH. However,
prospective well designed trials are needed to specifically
answer that question. A clinical trial of Bevacizumab with
chemotherapy in NSCLC patients is currently underway to
assess the safety of this form of antiangiogenic therapy after
radiation or surgery for brain metastases.
CONCLUSIONS
In metastatic NSCLC patients, the rates of spontaneous
ICH appeared to be higher in those with brain metastases
compared with those without, but were very low in both
groups. Most of the brain metastasis-associated ICH were not
symptomatic, detected during increased radiologic surveil-
lance. The rates of symptomatic ICH were not significantly
different between the two groups.
Patients with stable disease and history of radiation
therapy to the brain lesion may be reasonable candidates for
inclusion in antiangiogenic therapy trials. However, more
data from animal studies and well designed prospective trials
is still required to answer that question.
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